Foresite Capital Management V, LLC, 10% Owner at Latigo Biotherapeutics, Inc. (LTGO), bought 140,000 shares at $18.00 ($2.5M) on 2026-08-10, disclosed to the SEC on 2026-08-10.
Foresite Capital Management V, LLC purchased 140,000 shares for $2.52M at $18.00, marking the largest insider purchase in the company's history and signaling confidence in the biotech's non-opioid pain strategy. This significant capital commitment comes shortly after the company raised $345.6M in its IPO, potentially validating the recent market debut.
LTGO is currently trading at $18.74, just 7.02% above its 52-week low of $17.51 and 15.55% below its 52-week high of $22.19, indicating the stock is trading near the bottom of its recent range following its IPO.
Negative factors outweigh the positive ones.